2030 Diabetes Pharmaceutical Companies 
Pharmaceutical Technology
JUNE 7, 2023
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%
pharmaphorum
JUNE 27, 2025
Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 27, 2025
Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
pharmaphorum
OCTOBER 17, 2022
There’s no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to receive treatment, whilst also reducing risks like contamination and inappropriate use of reusable devices. Unfortunately, they have also been far from sustainable.
European Pharmaceutical Review
SEPTEMBER 21, 2023
billion by 2030. Pharmaceutical companies need to work closely with governments and health authorities to find innovative contracting and payment models, such as outcome-based agreements, which consider the clinical and economic value of the treatment to patients, healthcare systems and society. 1995; 270(5235): 475-480.
pharmaphorum
JUNE 16, 2025
Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
Fuld & Company Blog
MARCH 27, 2023
The background of semaglutide Nearly 20 years ago the first glucagon-like peptide 1 (GLP-1), a class of Type 2 diabetes drug that improves blood sugar, was launched, creating what is today a market worth nearly $30B. This market was estimated to be worth over $80 billion, in addition to the $30 billion diabetes market.
Expert insights. Personalized for you.
98 
Let's personalize your content